A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis

Talima Therapeutics

Status and phase: Terminated; Phase 2

Conditions: Distal Subungual Onychomycosis

Treatments: Drug: TMI-358; Drug: MMI-467

Study type: Interventional

Funder types: Industry

Identifiers

NCT01093118

TCP-TMI-7007

Details and patient eligibility

About

The purpose of this study is to determine if a local treatment is effective for the treatment of toenail fungus (distal subungual onychomycosis).

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, 18 to 75 years of age, inclusive

• Diagnosed with distal subungual onychomycosis (DSO) of the toenails

• Great toe(s) with intact skin and intact neurologic functions

• Great toenail(s) free of nail polish

• At least one target great toe which has:

  • 25 to 75% involvement of the area of the nail unit (including destroyed or missing parts of the nail plate)
  • at least 2 mm of uninvolved nail growth as measured from the proximal nail fold to the most proximal point to the disease process and with no lunular involvement
  • nail unit hyperkeratosis at the most distal edge which measures no greater than 3 mm
  • a positive KOH and culture

Exclusion criteria

• Any significant disease of the hepatic, renal, endocrine (including diabetes mellitus), immune systems, or other health conditions which could interfere with or confound the results of study assessments
• Pre-existing chronic foot pain, neurologic deficit or skin disease/injury in treated foot
• In the case of female subjects, are pregnant, nursing, or planning to become pregnant within the study period
• History of clinically significant abnormal laboratory values, including liver function test results equal to or greater than 2 x the upper limit of normal
• Disease-like psoriatic toenails, significant toenail abnormalities/dystrophies, toenail injuries or any other condition in the toenail which could interfere with study evaluations (e.g., prevent obtaining normal appearing nail, after clearing of onychomycosis, due to chemical damage, genetic or pigmentary disorders, etc.)
• Have white superficial onychomycosis, proximal subungual onychomycosis, yellow spikes, or dermatophytoma
• Have paronychia
• Have a history of chronic alcohol or drug abuse

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 2 patient groups, including a placebo group

TMI-358

Experimental group

Description:

Active treatment

Treatment:

Drug: TMI-358

MMI-467

Placebo Comparator group

Treatment:

Drug: MMI-467